Dr Laura Schmidt (NCI, USA) used high-throughput small molecule screens in FLCN-deficient human kidney cancer cell lines to identify several classes of compounds that were cytotoxic in vitro and subsequently tested their therapeutic efficacy in the FLCN-mutant Nihon rat renal tumor model. This evidence concerns the gene FLCN and kidney cancer.